aTyr Pharma (NASDAQ:ATYR) Reaches New 1-Year High - Still a Buy?

aTyr Pharma, Inc. (NASDAQ:ATYR - Get Free Report)'s share price reached a new 52-week high on Saturday . The stock traded as high as $6.44 and last traded at $5.99, with a volume of 5069655 shares changing hands. The stock had previously closed at $5.79.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on ATYR shares. Wells Fargo & Company boosted their target price on aTyr Pharma from $17.00 to $25.00 and gave the stock an "overweight" rating in a research report on Friday, June 20th. HC Wainwright reaffirmed a "buy" rating and issued a $35.00 target price on shares of aTyr Pharma in a research note on Wednesday, June 4th. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, aTyr Pharma has a consensus rating of "Buy" and an average price target of $20.20.

aTyr Pharma Stock Up 3.5%

The business's 50 day simple moving average is $4.82 and its 200-day simple moving average is $3.94. The company has a market cap of $533.13 million, a price-to-earnings ratio of -7.39 and a beta of 0.89. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.79 and a current ratio of 7.79.

aTyr Pharma (NASDAQ:ATYR - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported ($0.17) EPS for the quarter, beating analysts' consensus estimates of ($0.19) by $0.02. Sell-side analysts expect that aTyr Pharma, Inc. will post -0.91 earnings per share for the current year.

Hedge Funds Weigh In On aTyr Pharma

Large investors have recently modified their holdings of the stock. Group One Trading LLC acquired a new position in aTyr Pharma in the fourth quarter valued at approximately $26,000. Victory Capital Management Inc. bought a new position in shares of aTyr Pharma in the 4th quarter valued at about $37,000. Y Intercept Hong Kong Ltd bought a new position in shares of aTyr Pharma in the 1st quarter valued at about $38,000. Raymond James Financial Inc. bought a new position in shares of aTyr Pharma in the 4th quarter valued at about $39,000. Finally, XTX Topco Ltd bought a new position in shares of aTyr Pharma in the 4th quarter valued at about $40,000. 61.72% of the stock is currently owned by institutional investors and hedge funds.

About aTyr Pharma

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.